Moderna Vaccine Provokes Immunity in children 6 through 11

Moderna vaccine may boost immunity in children 6 to 11 years of age, scientists reported on Wednesday – another sign that it has become in the long run and abuse to protect children against the disease, although the spread is increasing.

On Monday, Moderna applied for approval from the Food and Drug Administration for vaccines used in this age group. But consent, if allowed, does not appear to result in fewer shots in many children.

The Pfizer-BioNTech vaccine has been available to children ages 5 through 11 since November, but as of Wednesday, only 28.7 percent had received two doses. There is no vaccine for coronavirus for all children under 5 years of age, forcing parents to rely on low-confidence prevention.

Last month, Moderna asked the FDA to approve its vaccine for children aged 6 months to 6 years. The agency has already reviewed the company’s records of young people, and is expected to decide on the use of Moderna vaccine for children of all ages in June.

In February, Pfizer and BioNTech also sought approval of their vaccine for use in minors, but withdrew the application after data showed the two doses did not produce vaccine. block enough for the Omicron variant.

The companies have released funding for a third vaccine in children, and the FDA is expected to review the data in June, as well.

Dr. “We can never do this in the future – we can never let children go to the end,” said Sallie Permar, a pediatric immunologist at Weill Cornell Medicine in New York.

The procedure has been particularly stressful and unfair for parents of the youngest children, who have not been vaccinated for more than two years for transmission, he said.

It has been almost a year since Moderna applied for FDA approval for the use of its vaccines to teens 12 to 17 years of age. When the agency offered the next move for Pfizer-BioNTech vaccine for use at that age in three weeks, the Moderna vaccine review agency was stopped.

The permit delay is the longest in the United States. European drug regulators have approved Moderna vaccine for adolescents aged 12 to 17 years, and have recommended it for children aged 6 to 11 years.

Authorities in Canada and Australia also approve Moderna vaccine for children 6 through 11 years of age.

In the United States, only one in four of the 28 million children between the ages of 5 and 11 is vaccinated against coronavirus. Parental dissatisfaction seems to be affected by the fact that the disease is known to be extremely dangerous in children.

Dr. Ofer Levy, director of immunization programs at Boston Children’s Hospital and a consultant to the FDA, said: “The risk of serious childhood infections is much, much, much lower – Let us be honest about it, “

Still, he said he had recently treated a leukemia child who was hospitalized for Covid. “Some of the children have received heavy Covid, some have been hospitalized,” he said, adding that more than 1,500 children under the age of 18 have died so far in the outbreak. .

Dr. “I am not in the right, but I think families should have a choice to protect their minority,” Levy said.

In his experiment, published in The New England Journal of Medicine, Moderna first tested several variations of his vaccine and chose a dose of 50 micrograms – half the dose for adults – for children. ages 6 to 11. Researchers later gave birth to more than 4,000 children. to receive two doses 28 days apart.

Three-quarters of the children received the vaccine, and the rest received placebo on saline. Approximately half of the children are from communities of color. To test the reaction force, scientists measured the reaction that develops after injection. (Pfizer’s experimental vaccine relies on the same method, called immunobridging.)

Children who receive the vaccine develop a vaccine that is slightly higher than that of adults, which is a promise. These experiments are not large enough to measure the vaccine’s ability to prevent serious illness or death.

But according to the smallpox virus with different Delta participants, the researchers estimated that the vaccine was effective against 88 percent of cases.

“Immunobridging is a predictive study that we have conducted – that the same level of immunity will be more similar to immunity in the younger age group than it was in the older age group,” Dr. Permar said. “So it’s good when you can follow the performance.”

Immunizations seem to produce minor side effects – including pain at the injection site, headaches and fatigue – and are less common in adults. About half of the children also have a fever, up to a day.

Outbreaks appear to be exacerbated during childhood and adolescence, as high fever in children may require screening to prevent dangerous infections. , Dr. Permar said.

The test is not large enough to detect rare side effects, such as heart problems that are seen in other age groups. The Pfizer-BioNTech vaccine appears to be less likely to cause myocarditis in children than adolescents or young adults.

Moderna experiments are testing the reaction energy against the Delta variant, and scientists are still testing its effectiveness against the Omicron. All vaccines have proved ineffective, in all age groups, against the Omicron variant.

Independent scientists have reported that Moderna vaccine stimulates the immune system in children aged 7 to 11 years, and in adolescents, against the Omicron variant and other pathogens. coronavirus disease.

But these vaccines seem to be getting worse, as they do in adults. “Perhaps the effectiveness of the vaccine, in terms of the effectiveness of the vaccine, will not be as high as the data in the real world,” Dr. Levy said.

Dr. Permar said he hopes the virus infects with the mutation of the vaccine being investigated in an emergency.

“We have to think of other ways to get involved with children and pregnant women in the trial first,” she said. “And we have to do that now, because the epidemic is going to happen to us before we want it to.”

Leave a Comment